Summary The response of KHT sarcomas to one, two, five or ten daily fractions of 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU), with and without misonidazole (MISO), was evaluated using delay of tumour regrowth as the measure of response. When CCNU was given as 2 dose fractions separated by 24h rather than as a single treatment, no extra dose was necessary to achieve a particular level of damage, suggesting a lack of damage repair. With increasing fraction number, however, an increasing total dose of drug was required to achieve a given effect, presumably to compensate for proliferation. Increasing drug doses also were readily tolerated (almost twice the LD50/7 for a single dose of CCNU resulted in no deaths when given in a 10 fraction treatment) indicating a large sparing of normal tissue toxicity when CCNU treatments were fractionated.
Over the last few years there has been increasing interest in potentiating the action of conventional chemotherapeutic drugs by the addition of a chemical radiosensitizing agent such as misonidazole (MISO) . There are now many reports, using different combinations of these drugs and a variety of mouse tumour models, which indicate a greater tumour-cell cytotoxicity than that seen in the dose-limiting normal tissues i.e. a therapeutic gain has been achieved (for reviews see McNally, 1982; Siemann, 1982a) .
As with the initial experimental evaluation of MISO as a radiation sensitizer, these chemopotentiation studies have primarily concentrated on combinations of single doses of the chemotherapeutic agent and sensitizer. While the single dose radiation studies demonstrated substantial enhancement ratios (Adams, 1977) , when fractionated irradiations were investigated, the sensitizing effect of MISO decreased as the X-ray dose per fraction decreased (Denekamp & Stewart, 1978; Hill and Bush, 1978) .
Currently little is known as to whether chemopotentiation by MISO is affected by drug treatment fractionation as has been observed for radiosensitization. This is of some clinical importance since, although chemotherapy treatment regimes differ widely according to the agent involved and the toxicities they produce, many involve multiple drug exposures. The present study therefore was undertaken to determine whether a loss of sensitization, similar to that seen with Xrays, also occurred when MISO was combined with fractionated chemotherapy. The combination of 1-(2-chlorethyl)-3-cyclohexyl-l-nitrosourea (CCNU) and MISO, was chosen as a model, for detailed investigation, since it is particularly effective in the KHT sarcoma (Siemann, 1981 (Siemann, , 1982b . Studies designed to compare the effect of single doses and fractionated treatments (2, 5 and 10 daily fractions of CCNU in the absence or presence of MISO) on the KHT sarcoma were performed. These investigations therefore were directly comparable to previously reported sensitization studies combining fractionated radiotherapy and MISO treatment in this tumour model (Hill and Bush, 1978) . For comparison, experiments were also performed to investigate the response of the RIF-1 tumour to multiple doses of cyclophosphamide (Cy) and MISO.
Materials and methods
Mice and tumours The experiments described were performed using either the KHT sarcoma (Kallman et al., 1967) or the RIF-l tumour (Twentyman et al., 1980) in female C3H/HeJ mice (8-14 weeks old), obtained from Jackson Laboratories, Bar Harbor, Maine. KHT cells were prepared from solid tumours by mechanical dissociation (Thomson & Rauth, 1974) and passaged in vivo every 2 weeks. RIF-1 tumour cells were maintained and passaged alternately in vitro and in vivo as described by Twentyman et al. (1980) Following treatment, tumour response was assessed by measuring growth delay. Tumours were measured three to five times a week, by passing the tumour-bearing leg through a plastic rod with holes of increasing diameter. The smallest hole the tumour-bearing leg would pass through was recorded and converted to a tumour weight using a calibration curve (Siemann et al., 1977; Siemann & Sutherland, 1980) . The number of days for each tumour to grow to 5 times the size at treatment was then determined. The median time for the tumours of each group of animals to reach this endpoint was calculated and plotted against drug dose. Confidence limits about the median were calculated using non-parametric statistics (Noether, 1971 (Siemann, 1982b) .
To determine the effect of drug treatment fractionation on chemopotentiation by MISO, a fixed dose of MISO (0.5mg g-1) was combined with 1, 2, 5 or 10 daily doses of CCNU. Figure 2 shows the single dose and two fraction data. At a sensitizer dose of 0.5mgg-' the enhancement of growth delay was a factor of -1.5 for the single dose treatment and 1.7 for the two fraction treatment.
To investigate whether enhanced tumour responses could be maintained when daily 0.5mg g-1 doses of MISO were combined with even smaller doses of CCNU per fraction, five and ten fraction treatments were evaluated. In addition, for these latter protocols, the effect of reducing the MISO dose per fraction from 0.5 to 0.2mgg-1 also was studied. The results of these experiments are shown in Figure 3 . A dose of 0.5mgg-1 MISO given with each CCNU dose resulted in enhancement ratios of 1.6 and 1.5 for the five and ten daily fraction protocols respectively (solid vs open symbols). When the lower dose of MISO (0.2mg g-1) was combined with daily doses of CCNU, enhanced tumour responses to CCNU also were observed (harlequin symbols). With this dose of MISO, both fractionation schedules led to ERs of 1.3-1.4. These values are similar to the previously published value of 1.3 measured for this tumour treated with a single dose of 0.25mgg-1 MISO plus CCNU (Siemann, 1982b) . At both sensitizer doses studied the results therefore indicate no loss of sensitization with fractionation.
The various dose fractionation studies can be compared by determining an isoeffect curve. This is illustrated in Figure 4 where the total dose required for each CCNU fractionation schedule to yield a regrowth time of 20 days was calculated for both CCNU alone and CCNU combined with MISO.
The data indicate that MISO potentiates the efficacy of CCNU not only at large doses per fraction but also that this potentiation is not lost as the dose per fraction is decreased.
This lack of a loss of potentiation with drug fractionation can also be seen in Figure 5 . This figure illustrates the results obtained when a fixed total dose of 30mgkg-1 CCNU is delivered either as a single treatment or as two, five, six, eight or ten equal daily fractions, administered with or without 0.5mg g-1 MISO accompanying every dose. When 30mgkg-1 CCNU is subdivided into five fractions or more, the resulting growth delay approaches that measured for untreated control tumours i.e. daily doses of 6mg kg-1 CCNU or less are insufficient to retard tumour growth significantly. However, the addition of MISO to even these low doses of the nitrosourea, which in themselves are totally ineffective, produced a significantly enhanced tumour response.
In order to determine whether the observed potentiation of CCNU by MISO was influenced by changes in the pharmacokinetics of the chemotherapeutic agent in the presence of MISO, CCNU plasma levels were determined in C3H mice exposed to 20mg kg-1 CCNU alone or simultaneously combined with 0.2 or 0.5mg g-1 MISO (Table I) . CCNU concentrations were bData shown are the mean + s.e. of 6-7 determinations each pooling the blood of 2-3 mice. determined 25 min after treatment using the procedure developed by Lee and Workman (1983) . This time was chosen on the basis of previous evaluations (Lee and Workman, 1983) which demonstrated that monitoring the CCNU plasma concentrations at this fixed time could readily detect the influence of MISO on the plasma clearance of the nitrosourea. The data in Table I indicate that the plasma clearance of CCNU was reduced somewhat by a MISO dose of 0.5mgg-1 but not significantly affected by a dose of 0.2mgg-1.
To assess normal tissue toxicity, WBC counts were made on blood samples taken from the tails of C3H mice. Siemann (1982b) and McNally et al. (1982) have previously reported a depression in the white cell count which reached a nadir between days 2 and 4 following single dose treatment with CCNU or CCNU plus MISO. Since it was not known whether fractionation might influence the time course of this response, blood samples were taken at 2 or 3 day intervals, from groups of 5 animals, for a total of 26 days following the initial treatment. Measurements were made following the five fraction schedule only; each mouse received a total of 50 mg kg-1 CCNU (5 x 10 mg kg-1) with or without 0.2 or 0.5mg g-1 MISO accompanying each dose. All three treatment schedules produced a drop in the WBC count over the first 4 days, followed by a gradual recovery. However, none of the counts returned to pretreatment levels over the full three weeks of measurement. MISO did not significantly enhance the white cell depression measured at the nadir, although there was a suggestion that those animals which received the combined treatment maintained a somewhat lower WBC count than those animals receiving CCNU alone. No consistent difference was seen between the responses of tumour-bearing and non-tumour bearing mice.
Since white cell depression was maximal between days 4 and 7, a dose-response relationship for the five fraction regimen was measured on day 5, after the completion of treatment. Figure 6 shows total WBC counts for animals treated with a range of CCNU doses with or without 0.2 or 0.5mgg-1 MISO accompanying each dose. There was no consistent enhancement of CCNU-induced WBC toxicity by MISO.
Differential cell counts of granulocytes, lymphocytes and monocytes revealed that the cells primarily affected by the treatment where the peripheral granulocytes. Four days after the start of treatment, the depression in WBC count was almost entirely due to granulocyte depletion and no difference could be detected between samples from animals which had received CCNU alone or CCNU plus MISO.
Growth delay experiments also were performed to assess the response of the RIF-1 tumour to repeated daily doses of Cy with or without 0.5mgg-1 MISO. Complete dose response curves were obtained for protocols combining MISO with a range of 1, 2, 5 or 10 daily dose fractions of Cy. From these the ERs measured at a regrowth time of 15 days, were calculated (Table II) . As was seen with CCNU, the degree of chemopotentiation measured remained unchanged whether MISO was combined with a single fraction or multiple daily dose fractions of Cy. McNally, 1982; Siemann, 1982a Siemann, , 1984 Millar, 1982 , for reviews). While most of the in vivo data concern tumour responses to large single doses of drugs, several studies have indicated that sensitization would not decrease with decreasing doses of the chemotherapeutic drug (Twentyman, 1981; Law et al., 1981; Hirst et al., 1982; Siemann, 1984 Figure 5 ).
The initial split-dose studies (Figure 1 ), showed that approximately equal levels of damage were produced by a particular drug dose whether it was delivered as a single treatment or as two equal fractions separated by 24h, suggesting the absence of any repair during this interval. As treatments were extended to five and ten fractions (Figure 3 ) extra dose was required to produce the same tumour effect, but this was probably due to proliferation. The tumours continue to grow throughout the treatment period, since cell death and removal does not occur at the time each dose is administered. Due to the rapid growth of the KHT sarcoma, (volume doubling time 1.5-2.5 days), fractionation could not be extended beyond the 10 day treatment period employed. At many of the dose levels used in both the five and ten fraction experiments, no tumour regression could be detected by the end of the course of treatment, although ultimately shrinkage did occur, followed by regrowth. Clinically, lack of tumour response during treatment is frequently used as a reason for terminating therapy with the drug in question. Clearly in this experimental situation, lack of responsiveness during treatment did not indicate lack of treatment effectiveness and would have proved a poor prognostic indicator.
As well as the dose sparing effect observed in the tumour, a large sparing of lethal toxicity also was seen with increasing fractionation. Using mice of the same sex and strain as those in the present study, Siemann (1981) , previously reported an LD50/7 value of 46.4 (44.4-48.6)(95% confidence limits)mgkg-1 CCNU, which was reduced to 38.8 (36.9-40.8)mgkg-1 on combination with 0.5mgg-1 MISO. In the present study greatly increased doses of drug were administered without approaching the LD50/7. No deaths occurred with a dose of 60mg kg-1 CCNU delivered in five fractions, or 90mgkg-1 in ten fractions i.e. practically double the dose which proved lethal to 50% of the animals when given as a single treatment. Similarly, when MISO was added to the treatment protocol, higher total doses of CCNU were tolerated when they were fractionated; 40 and 50mg kg-1 in five fractions and 50 and 80mgkg-1 in 10 fractions for 0.5 and 0.2mgg-1 MISO respectively. Since the doses did not extend to levels where any lethality was encountered, no estimate could be made of the increases in LD50 values resulting from the different protocols. However, the available data indicate that the increase in the tolerated dose is at least as large as the increase in the dose required to produce the same tumour effect. This suggests that there is no loss of therapeutic gain in progressing from one to ten fractions.
Myelosuppression is the primary dose-limiting toxicity of CCNU in man, which is manifest as a delayed leucopenia. Therefore, to further consider the question of therapeutic gain, we measured the total white cell count following treatment with CCNU with or without MISO, delivered in a five fraction protocol. The data illustrated in Figure 6 , measured at the time of peak white cell depression, did not indicate any significant enhancement of CCNU-induced WBC toxicity by MISO, again suggesting no loss of therapeutic gain.
Two previously published studies have included information on the effects of five daily fractions of Cy and MISO. Twentyman (1981) considered just two dose levels of Cy and measured the growth delay resulting from treatment with and without MISO (0.33mgg -1) in the RIF-l and KHT sarcomas. Single dose experiments with this dose of MISO produced only a small enhancement of Cy response in both tumour systems. On extending the treatments to five fractions an increase in growth delay was measured at the higher of the two Cy doses for the RIF-1 tumour, but toxicity was very high at this drug level, even without the addition of MISO. However, the response of the KHT tumour was significantly enhanced at both Cy doses. Extrapolation of the data suggested an ER of 1.5 which was significantly greater than the enhancement achieved by a single treatment. In a similar experiment, again using the RIF-l tumour, Law et al. (1981) The results presented here for the potentiation of CCNU damage by MISO are in direct contrast to the data obtained when MISO was tested as a radiation sensitizer (Hill & Bush, 1978; Denekamp & Stewart, 1978) . In these studies, large enhancement ratios were measured for single dose treatments, however, when the radiation dose was fractionated, the sensitizing effect of the drug decreased as the radiation dose per fraction decreased. Similarly, breathing carbogen (95% 02+5% CO2) was found to sensitize tumours to the effects of large single doses of radiation (by decreasing the hypoxic fraction), but again, sensitization decreased with fractionation and decreasing doses of radiation . The current data emphasize that the mechanism by which MISO potentiates the action of CCNU must be different from that by which both it and oxygen act as radiation sensitizers.
Several reasons have been put forward to explain the loss of radiation sensitization with decreasing dose per fraction. At low doses of radiation, the oxygen enhancement ratio (OER) has been found to be reduced (Palcic et al., 1982) . This would tend to imply that multiple small fractions should be more effective than large single doses of radiation, since the protected status of the hypoxic cells would be reduced, this would also reduce the degree of radiosensitization which be achieved. In addition, since it is the fully oxygenated radiosensitive cells within a tumour which will dominate its response when low radiation doses are used, the natural process of reoxygenation occuring between successive fractions may also serve to reduce the importance of hypoxic cells and therefore the benefit that might be gained by hypoxic cell sensitizers such as MISO. This is further supported by the observation that MISO affects the final, but not the initial slope of a radiation survival curve i.e. the # but not the the a component of the linear quadratic cell survival model (Palcic et al., 1983) . Since the a term dominates at low radiation doses, these data would again imply that MISO should be more effective at high radiation doses.
Several studies have suggested that MISO is a more efficient chemosensitizer when combined with low doses of the chemotherapeutic agent (Twentyman, 1981; Law et al., 1981; Hirst et al., 1982; Mulcahy et al., 1982) . It also has been noted, both in vitro and in vivo, that chemopotentiation frequently, though not always, occurs as a reduction or loss of the shoulder on the dose response curve, with little change in the final slope (Stratford et al., 1980; Siemann et al., 1984; RoizinTowle & Hall, 1981) . This suggested that fractionation might prove successful. The data presented here have indicated a cumulative effect of repeated low doses, with no evidence of repair processes occurring between subsequent fractions. Potentiation of CCNU damage appears to occur with every treatment (Figure 4) , even when the chemotherapy alone is totally ineffective in retarding tumour growth ( Figure 5 ). One explanation may be that chemosensitization occurs at least to some extent at oxygen levels above those required for radiobiological hypoxia. If (Mulcahy, 1984) . In addition it seems clear that, while hypoxic cells are necessary for chemopotentiation (McNally, 1982; Brown, 1982; Wheeler et al., 1984; Siemann, 1984) this effect is not restricted to the fraction of radiobiologically hypoxic tumour cells (Siemann, 1982a) . Finally, if modification of chemotherapeutic agent activity occurred at oxygen tensions above those associated with radiobiological hypoxia this also could play a role in the enhanced normal tissue toxicities associated with drug-sensitizer combinations.
Possible mechanisms for chemopotentiation have been extensively reviewed elsewhere (Brown, 1982; Millar, 1982; McNally, 1982; Siemann, 1982a Siemann, , 1984 and will not be addressed in detail here. It is possible however, to consider the importance of modification of cytotoxic drug pharmacokinetics by MISO in the context of the present experiments.
Considerable data now exist to indicate that sensitizers can alter the pharmacokinetics of a number of chemotherapeutic agents (Hinchliffe et al., 1983; Lee & Workman, 1983) . While failing to account for all the chemopotentiation results, pharmacokinetic changes are involved when chemotherapeutic agent efficacies are enhanced in vivo by large sensitizer doses (for review see Siemann, 1984) . Lee and Workman (1983) observed that the plasma clearance of CCNU was reduced as the MISO dose was increased, with a threshold MISO dose of approximately 0.3mg g-1. The current results (Table I) . which indicate that a MISO dose of 0.5mgg-1 reduced the clearance of CCNU while a 0.2mgg-1 dose had no effect, are consistent with those previous findings. The 0.2mgg-1 dose was sufficient, however, to achieve chemopotentiation in a fractionated dose protocol (Figures 3 and 4) suggesting that chemopotentiation can occur in the absence of a pharmacokinetic effect.
In summary, the present results indicate that unlike the loss of sensitization seen when MISO is added to fractionated radiation, no loss of potentiation occurred with fractionated CCNU plus MISO. In addition, repeated low dose treatments with both agents did not appear to increase the normal tissue toxicity above that achieved with a single high dose treatment, suggesting no loss of therapeutic benefit with fractionation. Further fractionated treatments aimed at determining the effectiveness of other drug combinations particularly with clinically relevant doses of MISO and utilizing several tumour models are indicated. Nevertheless, the benefits seen in this study suggest that MISO might be successfully added to repeated low dose chemotherapy treatments.
